Search results for "artery thrombosis"

showing 4 items of 4 documents

The Involvement of Toll-like Receptor-2 in Arterial Thrombus Formation.

2018

There is emerging evidence for the participation of toll-like receptor-2 (TLR2) expressed on platelets and endothelial cells in the setting of arterial thrombosis. In isolated human platelets, TLR2/1 activation was demonstrated to induce platelet activation, secretion, aggregation, adhesion to collagen coatings and the formation of platelet-leukocyte conjugates, whereas murine platelets were less sensitive to TLR2/1 stimulation. Also, endothelial cells can be activated by stimulation with TLR2 agonists, resulting in increased expression of adhesion molecules, synthesis of inflammatory mediators and Weibel-Palade body exocytosis. Endothelial TLR2 signalling promotes atherosclerotic lesion de…

0301 basic medicineBlood Platelets030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineVon Willebrand factormedicineAnimalsHumansPlateletPlatelet activationInflammationToll-like receptorbiologyCell adhesion moleculeChemistryEndothelial CellsCarotid Artery ThrombosisThrombosisHematologyArteriesmedicine.diseasePlatelet ActivationThrombosisPlaque AtheroscleroticToll-Like Receptor 2TLR2030104 developmental biologyCancer researchbiology.proteinHamostaseologie
researchProduct

Incidence of liver retransplantation and its effect on patient survival.

2008

Purpose. The purpose of this study was to review our institutional experience with re-liver transplantation (OLT) after split and full-size OLT. Patients and methods. We evaluated data corresponding to retransplanted patients over an 8-year period who underwent deceased donor OLT at our institution. Variables analyzed included indications for primary OLT, and re-OLT, the type of graft used during the initial versus re-OLT, the time from initial to re-OLT, and patient survival after re-OLT. Results. Sixty-four of 697 first OLT (9.2%) required re-OLT. Forty-nine cases were among 637 (7.6%) full-size OLT, while 15 were among 60 (25%) split OLT (P <.001). Median time to re-OLT was 8 days (range…

AdultMaleReoperationmedicine.medical_specialtyAdolescentYoung AdultOverall survivalMedicineHumansSurvivorsAgedRetrospective StudiesTransplantationDeceased donorbusiness.industryIncidence (epidemiology)Patient SelectionPatient survivalHepatitis CMiddle Agedmedicine.diseaseSurgeryLiver TransplantationTransplantationSurvival RateHepatic artery thrombosissurgical procedures operativeMedian timeSurgeryFemalebusinessTransplantation proceedings
researchProduct

A case of Brucella endocarditis in association with subclavian artery thrombosis.

2012

Brucellosis is a common zoonosis, endemic in Mediterranean countries, and caused by bacteria ofBrucellagenus. Brucellosis is a systemic infection and the clinical presentation varies widely from asymptomatic and mild to severe disease. Cardiovascular complications are extremely rare. We present a case of arterial thrombosis in a previously healthy young patient withBrucellaendocarditis. Careful attention must be paid to any sign or symptom of thrombosis in patients affected by brucellosis, regardless of the presence of endocarditis and cardiovascular risk factors.

Pediatricsmedicine.medical_specialtybiologybusiness.industryZoonosisBrucellosisCase ReportGeneral MedicineBrucellabrucellosi complicanze endocarditebiology.organism_classificationmedicine.diseaseSubclavian artery thrombosisAsymptomaticThrombosisSurgerylcsh:Infectious and parasitic diseasesmedicineEndocarditislcsh:RC109-216medicine.symptomSign or Symptombusiness
researchProduct

Antithrombotic treatment and outcomes of splanchnic vein thrombosis in an international prospective registry: Results of 2-year follow-up

2014

Abstract Background: Little information is available on the long-term clinical outcome of patients with splanchnic vein thrombosis (SVT). We aimed to assess incidence rates of bleeding, recurrence, and mortality in a large prospective cohort of SVT patients after a 2-year follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Information was gathered on baseline characteristics, risk factors and therapeutic strategies. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis, and mortality) during follow-up were collected and reviewed by a Central Adjudication Committee. Major bleeding was de…

medicine.medical_specialtymedicine.drug_classliver cirrhosisImmunologyanticoagulant agentBiochemistrymaleInternal medicinedeathMedicinefollow upartery thrombosishumanRisk factorProspective cohort studythrombosisriskregisteranticoagulant therapybusiness.industryhematologyIncidence (epidemiology)pathogenesisAnticoagulantCell Biologymedicine.diseasebleedingThrombosismortalitySurgeryVenous thrombosissocietySplanchnic vein thrombosisvein thrombosisrisk factorsolidincidenceantivitamin KpatientbusinessAmericanFibrinolytic agentneoplasmhospitalizationportal vein
researchProduct